Human anti-B7RP1 neutralizing antibodies

Details Human anti-B7RP1 neutralizing antibodies Human anti-B7RP1 neutralizing antibodies

2011-01-11

2011-01-11

Ouspenski, Ilia (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S130100

Reexamination Certificate

active

07868140

ABSTRACT:
This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4740461 (1988-04-01), Kaufman
patent: 4816397 (1989-03-01), Boss et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5625825 (1997-04-01), Rostoker et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6521749 (2003-02-01), Ling et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 7271245 (2007-09-01), Felding-Habermann et al.
patent: 7435796 (2008-10-01), Yoshinaga
patent: 7521532 (2009-04-01), Dunussi-Joannopoulos et al.
patent: 7601813 (2009-10-01), Ling et al.
patent: 7708993 (2010-05-01), Yoshinaga et al.
patent: 036676 (1981-09-01), None
patent: 0058481 (1982-08-01), None
patent: 088046 (1983-09-01), None
patent: 133988 (1985-03-01), None
patent: 143949 (1985-06-01), None
patent: PCT/US93/00829 (1993-08-01), None
patent: PCT/US94/001875 (1994-09-01), None
patent: 1374902 (2004-01-01), None
patent: WO 88/01649 (1988-03-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22646 (1992-12-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/56772 (2000-09-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 02/04364 (2002-06-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO2004043989 (2004-05-01), None
patent: WO2004106380 (2004-12-01), None
patent: WO 2006/003999 (2006-01-01), None
Sequence alighnment with Korman, 1 page.
Sequence alignment with Felding-Habermann, 1 page.
Blazer et al., J. Immunol., 1996, 157: 3250-3259.
S. Khayyamian et al., “ICOS-ligand, Expressed on Human Endothelial Cells, Costimulates H1 and Th2 Cytokine Secretion by Memory CD4+ T Cells,” PNAS, vol. 99, No. 9, p. 6198-6203 (2002).
Iwai H. et al., “Amelioration of Collagen-Included Arthritis by Blockade of Inducibe Costimulator-B7 Homologous Protein Costimulation-B7 Homologous Protein Costimulation,” Journal of Immunology, p. 4332-4339 (2002).
Totsuka Teruji et al., “Amerliorating effect of Anti-Inducible Costimulator Monoclonal Antibody in a Murine Model of Chronic Cloitis,” Gastroenterology, p. 410-421 (2003).
G. Richter et al., “Tumor Necrosis Factor-Alpha Regulates the Expression of Inducible Costimulator Receptor ligand on CD34+ Progenitor Cells During Differentiation into Antigen Presenting Cells,” The Journal of Bilogical Chemistry, vol. 276, No. 49, p. 45686-45693 (2001).
P. Whal et al., “Renal Tubular Epithelial Expression of the Costimulatory Molecule B7RP-1 (Inducible Costimulator Ligand),” Journal of the American Society of Nephrology, vol. 13, p. 1517-1526 (2002).
P. Wahl et al., “Interaction of B&RP1 with ICOS Nagatively Reulates Antigen Presentation by B Cells,” Inflammation, vol. 27, No. 4, p. 191-200 (2003).
Abrams et al., 2000, “Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells”, J Exp Med. 192(5):681-94.
Abrams et al., 1999, “CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris”, J. Clin. Invest. 103(9):1243-52.
Kremer et al., 2003, “Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig”, New England Journal of Medicine 349(20):1907-15.
Yoshinga et al., 2000, “Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS”, Int. Immun. 12(10):1439-47.
Coyle et al., 2000, “The CD28-related molecule ICOS is required for effective T cell-dependent immune responses”, Immunity 13(1):95-105.
Yoshinaga et al., 1999, “T-cell co-stimulation through B7RP-1 and ICOS”, Nature. 402(6763):827-32.
McAdam et al., 2000, “Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells”, Journal of Immunology 165(9):5035-40.
Dong et al., 2003, “Regulation of immune and autoimmune responses by ICOS”, Journal of Autoimmunity. 21:255-60.
LaPlanche et al., 1986, “Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric O-ethyl phosphorothioates”, Nucl. Acids Res., 14(22):9081-93.
Stec et al., 1984, “Automated solid phase synthesis, separation and stereochemistry of phosphothioate analogues of oligodeoxyribonucleotides”, J. Am. Chem. Soc., 106:6077.
Stein et al., 1988, “Physicochemical properties of phosphorothioate oligodeoxynucleotides”, Nucl. Acids Res., 16(8):3209-21.
Zon et al., 1991, “Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions”, Anti-Cancer Drug Design, 6(6):539-68.
Zon et al., 1991, Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed.), Oxford University Press, Oxford England.
Uhlmann and Peyman, 1990, “Antisense oligonucleotides: a new therapeutic principle”, Chemical Reviews, 90:543.
Frisque et al., 1973, “Infectivity of the DNA from four isolates of JC virus”, Virology 32(2):476-82.
Chu et al., 1981, “SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen”, Gene 13(2):197-202.
Burton and Woof, 1992, “Human antibody effector function”, Advances in Immunology 51:1-84.
Ravetch and Bolland, 2001, “IgG Fc receptors”, Annu. Rev. Immunol. 19:275-90.
Shields et al., 2001, “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R”, Journal of Biol. Chem 276(9):6591-604.
Telleman and Junghans, 2000, “The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile”, Immunology 100(2):245-51.
Medesan et al., 1998, “Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site”, Eur. J. Immunol. 28(7):2092-100.
Thornton et al., 1991, “Protein structure. Prediction of progress at last”, Nature 354(6349):105-6.
Taylo

Affiliated with

Also associated with

Rating

Human anti-B7RP1 neutralizing antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human anti-B7RP1 neutralizing antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-B7RP1 neutralizing antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2730993